Pharmacological management of atopic dermatitis in the elderly

References

• Katsarou A, Armenaka M. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol. 2011 Jan;25(1):12–18.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Leung DYM, Eichenfield LF, et al. Atopic Dermatitis. In: Kang S, Amagai M, Bruckner AL, et al., editors. Fitzpatrick’s Dermatology, 9e. New York, NY: McGraw-Hill Education; 2019 Aug 29.
   Google Scholar
• Bieber T. Atopic dermatitis. N Engl J Med. 2008 Apr 3;358(14):1483–1494.
   PubMed Web of Science ®Google Scholar
• Furue M, Ulzii D, Vu YH, et al. Pathogenesis of Atopic Dermatitis: current Paradigm. Iran J Immunol. 2019 Jun;16(2):97–107.
   PubMed Web of Science ®Google Scholar
• Tanei R, Hasegawa Y. Atopic dermatitis in older adults: A viewpoint from geriatric dermatology. Geriatr Gerontol Int. 2016 Mar;16(Suppl 1):75–86.
   PubMedGoogle Scholar
• Tanei R, Katsuoka K. Clinical analyses of atopic dermatitis in the aged. J Dermatol. 2008 Sep;35(9):562–569.
   PubMed Web of Science ®Google Scholar
• Wolkewitz M, Rothenbacher D, Low M, et al. Lifetime prevalence of self-reported atopic diseases in a population-based sample of elderly subjects: results of the ESTHER study. Br J Dermatol. 2007 Apr;156(4):693–697.
   PubMed Web of Science ®Google Scholar
• Bozek A, Fisher A, Filipowska B, et al. Clinical features and immunological markers of atopic dermatitis in elderly patients. Int Arch Allergy Immunol. 2012;157(4):372–378.
   PubMed Web of Science ®Google Scholar
• Jaworek A, Szafraniec K, Pastuszczak M, et al. The knowledge of issues associated with topical corticosteroids using in patients with atopic dermatitis. Pol Merkur Lekarski. 2019 Jun 28;46(276):243–247.
   PubMedGoogle Scholar
• Cao T, Tey HL, Yosipovitch G. Chronic pruritus in the geriatric population. Dermatol Clin. 2018 Jul;36(3):199–211.
   PubMed Web of Science ®Google Scholar
• Chiang C, Eichenfield LF. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. Pediatr Dermatol. 2009;26(3):273–278.
   PubMed Web of Science ®Google Scholar
• Giam YC, Hebert AA, Dizon MV, et al. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy. 2016;6(2):120–128.
   PubMed Web of Science ®Google Scholar
• Harrison IP, Spada F. Breaking the itch–scratch cycle: topical options for the management of chronic cutaneous itch in atopic dermatitis. Medicines. 2019;6(3):76.
   Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014 Jul;71(1):116–132.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Eucrisa (crisaborole) ointment. 2017 Sep 01. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207695Orig1s000TOC.cfm
   Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014 Aug;71(2):327–349.
   PubMed Web of Science ®Google Scholar
• Administration UFaD. DUPIXENT®(dupilumab) injection, for subcutaneous use. 2017.
   Google Scholar
• Breternitz M, Kowatzki D, Langenauer M, et al. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol Physiol. 2008;21(1):39–45.
   PubMed Web of Science ®Google Scholar
• Moncrieff G, Cork M, Lawton S, et al. Use of emollients in dry-skin conditions: consensus statement. Clin Exp Dermatol. 2013 Apr;38(3):231–238. quiz 38.
   PubMed Web of Science ®Google Scholar
• Harrison IP, Spada F. Breaking the itch-scratch cycle: topical options for the management of chronic cutaneous itch in atopic dermatitis. Medicines (Basel). 2019 Jul 18;6:3.
   Google Scholar
• Ishikawa J, Narita H, Kondo N, et al. Changes in the ceramide profile of atopic dermatitis patients. J Invest Dermatol. 2010 Oct;130(10):2511–2514.
   PubMed Web of Science ®Google Scholar
• Joo KM, Hwang JH, Bae S, et al. Relationship of ceramide-, and free fatty acid-cholesterol ratios in the stratum corneum with skin barrier function of normal, atopic dermatitis lesional and non-lesional skins. J Dermatol Sci. 2015 Jan;77(1):71–74.
   PubMed Web of Science ®Google Scholar
• Angelova-Fischer I, Rippke F, Richter D, et al. Stand-alone emollient treatment reduces flares after discontinuation of topical steroid treatment in atopic dermatitis: a double-blind, randomized, vehicle-controlled, left-right comparison study. Acta Derm Venereol. 2018 Apr 27;98(5):517–523.
   PubMed Web of Science ®Google Scholar
• Chang ALS, Chen SC, Osterberg L, et al. A daily skincare regimen with a unique ceramide and filaggrin formulation rapidly improves chronic xerosis, pruritus, and quality of life in older adults. Geriatr Nurs. 2018 Jan - Feb;39(1):24–28.
   PubMed Web of Science ®Google Scholar
• Draelos ZD, Raymond I. The efficacy of a ceramide-based cream in mild-to-moderate atopic dermatitis. J Clin Aesthet Dermatol. 2018 May;11(5):30–32.
   PubMedGoogle Scholar
• Gutman AB, Kligman AM, Sciacca J, et al. Soak and smear: a standard technique revisited. Arch Dermatol. 2005 Dec;141(12):1556–1559.
   PubMedGoogle Scholar
• Kohn LL, Kang Y, Antaya RJ. A randomized, controlled trial comparing topical steroid application to wet versus dry skin in children with atopic dermatitis (AD). J Am Acad Dermatol. 2016 Aug;75(2):306–311.
   PubMed Web of Science ®Google Scholar
• Wehner J, Neuber K. Staphylococcus aureus enterotoxins induce histamine and leukotriene release in patients with atopic eczema. Br J Dermatol. 2001 Aug;145(2):302–305.
   PubMed Web of Science ®Google Scholar
• Huang JT, Abrams M, Tlougan B, et al. Treatment of staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009 May;123(5):e808–14.
   PubMed Web of Science ®Google Scholar
• Papier A, Strowd LC. Atopic dermatitis: a review of topical nonsteroid therapy. Drugs Context. 2018;7:212521.
   PubMedGoogle Scholar
• Hoy SM. Crisaborole ointment 2%: a review in mild to moderate atopic dermatitis. Am J Clin Dermatol. 2017 Dec;18(6):837–843.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014 Dec;71(6):1218–1233.
   PubMed Web of Science ®Google Scholar
• Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1–191.
   PubMedGoogle Scholar
• Mehta AB, Nadkarni NJ, Patil SP, et al. Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 2016 Jul-Aug;82(4):371–378.
   PubMed Web of Science ®Google Scholar
• Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician. 2009 Jan 15;79(2):135–140.
   PubMed Web of Science ®Google Scholar
• Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for the use of topical glucocorticosteroids. American academy of dermatology. J Am Acad Dermatol. 1996 Oct;35(4):615–619.
   PubMedGoogle Scholar
• Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007;156(2):203–221.
   PubMed Web of Science ®Google Scholar
• Walsh P, Aeling JL, Huff L, et al. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol. 1993 Sep;29(3):501–503.
   PubMed Web of Science ®Google Scholar
• Kerns ML, Chien AL, Kang S, et al. Skin Aging. In: Kang S, Amagai M, Bruckner AL, et al., editors. Fitzpatrick’s dermatology, 9e. New York, NY: McGraw-Hill Education; 2019 Sep 02.
   Google Scholar
• Kiani A, Rao A, Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity. 2000 Apr;12(4):359–372.
   PubMed Web of Science ®Google Scholar
• Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol. 2005;6(2):65–77.
   PubMed Web of Science ®Google Scholar
• Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992 Apr;13(4):136–142.
   PubMedGoogle Scholar
• Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs. 2000 Jan;9(1):69–77.
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005;330(7490):516.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Baurecht H, Schmitt J. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal. Br J Dermatol. 2017 Oct;177(4):999–1003.
   PubMed Web of Science ®Google Scholar
• Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin. 2008 Apr;24(4):985–994.
   PubMed Web of Science ®Google Scholar
• Ruer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2009;26(5):551–558.
   PubMed Web of Science ®Google Scholar
• Thaci D, Chambers C, Sidhu M, et al. Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol. 2010 Sep;24(9):1040–1046.
   PubMed Web of Science ®Google Scholar
• Breneman D, Fleischer AB, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008 Jun 01;58(6):990–999.
   PubMed Web of Science ®Google Scholar
• Frankel HC, Qureshi AA. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis. Am J Clin Dermatol. 2012 Apr 1;13(2):113–123.
   PubMed Web of Science ®Google Scholar
• Remitz A, Kyllönen H, Granlund H, et al. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol. 2001 Jan 01;107(1):196–197.
   PubMed Web of Science ®Google Scholar
• Koo JYM, Fleischer AB, Abramovits W, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol. 2005 Aug 01;53(Supplement 2):S195–S205.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013 June 01;14(3):163–178.
   PubMed Web of Science ®Google Scholar
• Freund YR, Akama T, Alley MR, et al. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett. 2012 Sep 21;586(19):3410–3414.
   PubMed Web of Science ®Google Scholar
• Eichenfield LFM, Friedlander SFM, Simpson ELMM, et al. Assessing the new and emerging treatments for atopic dermatitis. Semin Cutan Med Surg. 2016 Jun;35(5 Suppl):S92–6.
   PubMedGoogle Scholar
• Wang D, Beck LA. Immunologic targets in atopic dermatitis and emerging therapies: an update. Am J Clin Dermatol. 2016 Oct;17(5):425–443.
   PubMed Web of Science ®Google Scholar
• Woo TE, Kuzel P. Crisaborole 2% ointment (Eucrisa) for atopic dermatitis. Skin Therapy Lett. 2019 Mar;24(2):4–6.
   PubMedGoogle Scholar
• Joseph F, Robert S, Andrea Z, David P, Fran C-B.Crisaborole ointment improves global atopic dermatitis severity: pooled results from two phase 3 clinical trials. J Am Acad Dermatol. 2017;76(6):AB86.
   Web of Science ®Google Scholar
• Callender VD, Alexis AF, Stein Gold LF, et al. Efficacy and safety of crisaborole ointment, 2%, for the treatment of mild-to-moderate atopic dermatitis across racial and ethnic groups. Am J Clin Dermatol. 2019 Jul 1:711–723.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017 Oct;77(4):641–49.e5.
   PubMed Web of Science ®Google Scholar
• Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016 Sep;75(3):494–503.e6.
   PubMed Web of Science ®Google Scholar
• Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000 Jun;9(3):165–169.
   PubMed Web of Science ®Google Scholar
• Chong JH, Koh MJA. Non-topical management of recalcitrant paediatric atopic dermatitis. Arch Dis Child. 2017 Jul;102(7):681–686.
   PubMed Web of Science ®Google Scholar
• Czech W, Brautigam M, Weidinger G, et al. A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol. 2000 Apr;42(4):653–659.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Koelle EU. Cyclosporin pharmacokinetics in the elderly. Drugs Aging. 1999 Sep;15(3):197–205.
   PubMed Web of Science ®Google Scholar
• Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002 Aug;147(2):324–330.
   PubMed Web of Science ®Google Scholar
• Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006 Mar 11;367(9513):839–846.
   PubMed Web of Science ®Google Scholar
• Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011 Aug;128(2):353–359.
   PubMed Web of Science ®Google Scholar
• Prezzano JC, Beck LA. Long-term treatment of atopic dermatitis. Dermatol Clin. 2017 Jul;35(3):335–349.
   PubMed Web of Science ®Google Scholar
• Shaffrali FC, Colver GB, Messenger AG, et al. Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol. 2003 Mar;48(3):417–419.
   PubMed Web of Science ®Google Scholar
• Goujon C, Viguier M, Staumont-Salle D, et al. Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial. J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):562–69.e3.
   PubMed Web of Science ®Google Scholar
• Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am. 1997 Nov;23(4):739–755.
   PubMed Web of Science ®Google Scholar
• Bressolle F, Bologna C, Kinowski JM, et al. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis. 1998;57(2):110–113.
   PubMed Web of Science ®Google Scholar
• Haeck IM, Knol MJ, Ten Berge O, et al. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol. 2011 Jun;64(6):1074–1084.
   PubMed Web of Science ®Google Scholar
• Yu SH, Drucker AM, Lebwohl M, et al. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018 Apr;78(4):733–40.e11.
   PubMed Web of Science ®Google Scholar
• Johnson BB, Franco AI, Beck LA, et al. Treatment-resistant atopic dermatitis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:181–192.
   PubMed Web of Science ®Google Scholar
• Wang FP, Tang XJ, Wei CQ, et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. J Dermatol Sci. 2018 May;90(2):190–198.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Scalvenzi M, et al. Effectiveness of dupilumab for the treatment of generalized prurigo nodularis phenotype of adult atopic dermatitis. Dermatitis. 2020 Jan 3; 31:81–84.
   PubMed Web of Science ®Google Scholar
• Brummer GC, Wang LT, Sontheimer RD. A possible role for dupilumab (Dupixent) in the management of idiopathic chronic eczematous eruption of aging. Dermatol Online J. 2018 15;24(2):Feb.
   Google Scholar
• Renert-Yuval Y, Guttman-Yassky E. What’s new in atopic dermatitis. Dermatol Clin. 2019 Apr;37(2):205–213.
   PubMed Web of Science ®Google Scholar